董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Gaugh | 男 | Independent Director | 73 | 28.47万美元 | 未持股 | 2026-04-06 |
| Jacob Liawatidewi | 男 | Executive Vice President of Sales and Marketing, Executive Vice President of Corporate Administration Center,President of Amphastar France Pharmaceuticals, S.A.S., and Director | 52 | 203.79万美元 | 19.73 | 2026-04-06 |
| Gayle Deflin | 女 | Independent Director | 63 | 34.00万美元 | 4.78 | 2026-04-06 |
| Richard Prins | 男 | Lead Independent Director | 69 | 37.75万美元 | 7.49 | 2026-04-06 |
| Jack Yongfeng Zhang | 男 | Chief Executive Officer, President, Chief Scientific Officer and Director | 79 | 830.94万美元 | 1242.17 | 2026-04-06 |
| Mary Ziping Luo | 女 | Director,Chief Operating Officer, Chief Scientist and Chairman of the Board | 76 | 403.11万美元 | 1242.17 | 2026-04-06 |
| William J. Peters | 男 | Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director | 58 | 323.87万美元 | 32.14 | 2026-04-06 |
| Diane G. Gerst | 女 | Independent Director | 66 | 32.78万美元 | 5.71 | 2026-04-06 |
| Howard Lee | 男 | Independent Director | 64 | 33.35万美元 | 21.88 | 2026-04-06 |
| Michael A. Zasloff | 男 | Independent Director | 80 | 33.10万美元 | 11.30 | 2026-04-06 |
| Floyd F. Petersen | 男 | Independent Director | 82 | 32.50万美元 | 13.82 | 2026-04-06 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Rong Zhou | 男 | Executive Vice President of Scientific Affairs and President of Amphastar Nanjing Pharmaceuticals, Co., Ltd. and Senior Executive Vice President of Production Center | 67 | 254.26万美元 | 47.62 | 2026-04-06 |
| Jacob Liawatidewi | 男 | Executive Vice President of Sales and Marketing, Executive Vice President of Corporate Administration Center,President of Amphastar France Pharmaceuticals, S.A.S., and Director | 52 | 203.79万美元 | 19.73 | 2026-04-06 |
| Jack Yongfeng Zhang | 男 | Chief Executive Officer, President, Chief Scientific Officer and Director | 79 | 830.94万美元 | 1242.17 | 2026-04-06 |
| Mary Ziping Luo | 女 | Director,Chief Operating Officer, Chief Scientist and Chairman of the Board | 76 | 403.11万美元 | 1242.17 | 2026-04-06 |
| William J. Peters | 男 | Chief Financial Officer, Executive Vice President of Finance, Treasurer, President of International Medication Systems, Limited, and Director | 58 | 323.87万美元 | 32.14 | 2026-04-06 |
董事简历
中英对照 | 中文 | 英文- David Gaugh
-
David Gaugh自2025年7月起担任Amphastar Pharmaceuticals, Inc.董事会成员。自2025年1月以来，Gaugh先生一直担任制药咨询公司Riley Pharmaceuticals的负责人。此前，从2012年2月至2025年1月，Gaugh先生任职于无障碍药品协会，这是一个代表仿制药处方药制造商和大宗医药化学品制造商的行业协会，从2022年7月至2025年1月担任执行副总裁（包括从2023年至2025年担任两年的临时总裁和首席执行官），并从2012年2月至2022年7月担任科学和监管事务高级副总裁。Gaugh先生目前担任AMHIC的董事会成员，此前曾在美国卫生协会系统药剂师基金会董事会、美国药物教育基金会董事会、加强FDA董事会联盟、无障碍药品协会董事会和USP公约理事会任职。Gaugh先生获得了怀俄明大学的药学学士学位，并获得了奥本大学商学院、加州大学洛杉矶分校、安德森商学院、南方卫理公会大学、考克斯商学院和密歇根大学罗斯商学院的高级培训。
David Gaugh has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since July 2025. Mr. Gaugh has served as the Principal at Riley Pharmaceuticals, a pharmaceutical consulting firm, since January 2025. Previously, from February 2012 until January 2025, Mr. Gaugh worked for the Association for Accessible Medicines, a trade association representing the manufacturers of generic prescription drugs and manufacturers of bulk pharmaceutical chemicals, serving as the Executive Vice President (including two years as the Interim President and CEO from 2023 to 2025) from July 2022 until January 2025 and as the Senior Vice President for Sciences and Regulatory Affairs from February 2012 until July 2022. Mr. Gaugh currently serves on the Board of Directors of AMHIC, and previously served on the American Society of Health System Pharmacists Foundation Board of Directors, the American Foundation for Pharmaceutical Education Board of Directors, the Alliance for a Stronger FDA Board of Directors, the Association for Accessible Medicines Board of Directors, and the USP Council of Convention. Mr. Gaugh received a BS, pharmacy from the University of Wyoming and advanced training from the Auburn University College of Business, the University of California, Los Angeles, Anderson School of Business, the Southern Methodist University, Cox School of Business, and the University of Michigan, Ross School of Business. - David Gaugh自2025年7月起担任Amphastar Pharmaceuticals, Inc.董事会成员。自2025年1月以来，Gaugh先生一直担任制药咨询公司Riley Pharmaceuticals的负责人。此前，从2012年2月至2025年1月，Gaugh先生任职于无障碍药品协会，这是一个代表仿制药处方药制造商和大宗医药化学品制造商的行业协会，从2022年7月至2025年1月担任执行副总裁（包括从2023年至2025年担任两年的临时总裁和首席执行官），并从2012年2月至2022年7月担任科学和监管事务高级副总裁。Gaugh先生目前担任AMHIC的董事会成员，此前曾在美国卫生协会系统药剂师基金会董事会、美国药物教育基金会董事会、加强FDA董事会联盟、无障碍药品协会董事会和USP公约理事会任职。Gaugh先生获得了怀俄明大学的药学学士学位，并获得了奥本大学商学院、加州大学洛杉矶分校、安德森商学院、南方卫理公会大学、考克斯商学院和密歇根大学罗斯商学院的高级培训。
- David Gaugh has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since July 2025. Mr. Gaugh has served as the Principal at Riley Pharmaceuticals, a pharmaceutical consulting firm, since January 2025. Previously, from February 2012 until January 2025, Mr. Gaugh worked for the Association for Accessible Medicines, a trade association representing the manufacturers of generic prescription drugs and manufacturers of bulk pharmaceutical chemicals, serving as the Executive Vice President (including two years as the Interim President and CEO from 2023 to 2025) from July 2022 until January 2025 and as the Senior Vice President for Sciences and Regulatory Affairs from February 2012 until July 2022. Mr. Gaugh currently serves on the Board of Directors of AMHIC, and previously served on the American Society of Health System Pharmacists Foundation Board of Directors, the American Foundation for Pharmaceutical Education Board of Directors, the Alliance for a Stronger FDA Board of Directors, the Association for Accessible Medicines Board of Directors, and the USP Council of Convention. Mr. Gaugh received a BS, pharmacy from the University of Wyoming and advanced training from the Auburn University College of Business, the University of California, Los Angeles, Anderson School of Business, the Southern Methodist University, Cox School of Business, and the University of Michigan, Ross School of Business.
- Jacob Liawatidewi
-
Jacob Liawatidewi自2022年8月起担任Amphastar Pharmaceuticals, Inc.董事会成员，自2020年5月起担任销售和营销执行副总裁兼公司行政中心执行副总裁，自2020年12月起担任Amphastar France Pharmaceuticals，S.A.S.（Amphastar的全资子公司）总裁，自2013年6月起担任公司秘书。Liawatidewi先生分别于2014年3月和2013年12月担任企业行政中心高级副总裁和销售与市场营销高级副总裁，直至晋升为执行副总裁。Liawatidewi先生自2012年8月起担任销售和营销副总裁，直至晋升为高级副总裁。2005年8月至2012年8月，Liawatidewi先生担任Amphastar Pharmaceuticals, Inc.的销售和市场营销副总裁。从1997年6月加入Amphastar Pharmaceuticals，Inc.到2005年8月，Liawatidewi先生曾在Amphastar Pharmaceuticals, Inc.的业务发展、销售和营销部门担任多个职务。Liawatidewi先生于1996年获得加州州立大学弗雷斯诺分校的生物学学士学位，2014年获得国立大学的工商管理硕士学位，2022年获得协和法学院的法学博士学位。
Jacob Liawatidewi has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since August 2022, Executive Vice President of Sales and Marketing and Executive Vice President of Corporate Administration Center since May 2020, President of Amphastar France Pharmaceuticals, S.A.S. (a wholly owned subsidiary of Amphastar) since December 2020, and Corporate Secretary since June 2013. Mr. Liawatidewi served as Senior Vice President of Corporate Administration Center and Senior Vice President of Sales and Marketing from March 2014 and December 2013, respectively, until his promotion to Executive Vice President. Mr. Liawatidewi served as Vice President of Sales and Marketing from August 2012 until his promotion to Senior Vice President. From August 2005 to August 2012, Mr. Liawatidewi was Amphastar Pharmaceuticals, Inc.'s Associate Vice President of Sales and Marketing. From joining Amphastar Pharmaceuticals, Inc. in June 1997 to August 2005, Mr. Liawatidewi held various roles in Amphastar Pharmaceuticals, Inc.'s business development, sales and marketing department. Mr. Liawatidewi received a B.S. in Biology from California State University of Fresno in 1996, an M.B.A. from National University in 2014, and an E.J.D. from Concord Law School in 2022. - Jacob Liawatidewi自2022年8月起担任Amphastar Pharmaceuticals, Inc.董事会成员，自2020年5月起担任销售和营销执行副总裁兼公司行政中心执行副总裁，自2020年12月起担任Amphastar France Pharmaceuticals，S.A.S.（Amphastar的全资子公司）总裁，自2013年6月起担任公司秘书。Liawatidewi先生分别于2014年3月和2013年12月担任企业行政中心高级副总裁和销售与市场营销高级副总裁，直至晋升为执行副总裁。Liawatidewi先生自2012年8月起担任销售和营销副总裁，直至晋升为高级副总裁。2005年8月至2012年8月，Liawatidewi先生担任Amphastar Pharmaceuticals, Inc.的销售和市场营销副总裁。从1997年6月加入Amphastar Pharmaceuticals，Inc.到2005年8月，Liawatidewi先生曾在Amphastar Pharmaceuticals, Inc.的业务发展、销售和营销部门担任多个职务。Liawatidewi先生于1996年获得加州州立大学弗雷斯诺分校的生物学学士学位，2014年获得国立大学的工商管理硕士学位，2022年获得协和法学院的法学博士学位。
- Jacob Liawatidewi has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since August 2022, Executive Vice President of Sales and Marketing and Executive Vice President of Corporate Administration Center since May 2020, President of Amphastar France Pharmaceuticals, S.A.S. (a wholly owned subsidiary of Amphastar) since December 2020, and Corporate Secretary since June 2013. Mr. Liawatidewi served as Senior Vice President of Corporate Administration Center and Senior Vice President of Sales and Marketing from March 2014 and December 2013, respectively, until his promotion to Executive Vice President. Mr. Liawatidewi served as Vice President of Sales and Marketing from August 2012 until his promotion to Senior Vice President. From August 2005 to August 2012, Mr. Liawatidewi was Amphastar Pharmaceuticals, Inc.'s Associate Vice President of Sales and Marketing. From joining Amphastar Pharmaceuticals, Inc. in June 1997 to August 2005, Mr. Liawatidewi held various roles in Amphastar Pharmaceuticals, Inc.'s business development, sales and marketing department. Mr. Liawatidewi received a B.S. in Biology from California State University of Fresno in 1996, an M.B.A. from National University in 2014, and an E.J.D. from Concord Law School in 2022.
- Gayle Deflin
-
Gayle DeFlin自2021年6月起担任Amphastar Pharmaceuticals, Inc.董事会成员。Deflin女士自2014年起担任LBMB，Inc.及其子公司Plasticolor Molded Products，Inc.和Chroma Graphics，Inc.的首席财务官，这两家公司均为汽车配件制造商和分销商，自2006年起担任该公司的职务。在2006年之前，DeFlin女士曾于2004年至2006年在家庭呼吸服务提供商Apria Healthcare任职，担任战略规划和预算副总裁以及计费中心运营副总裁。从2003年到2004年，她担任Ionian Technologies的总裁兼首席执行官，这是一家在凯克应用生命科学研究所开发的生物技术诊断初创公司。Deflin女士于1989年在International Medication Systems Limited担任多个职位，包括担任总裁，直到该公司于1998年被出售给Amphastar。她于1996年至2002年继续在International Medication Systems，Limited的前所有者Celltech Pharmaceuticals担任MD Pharmaceuticals总裁，并于2000年至2002年担任Celltech Pharmaceuticals业务支持服务高级副总裁。Deflin女士拥有鲍灵格林州立大学工商管理（会计学和管理信息系统）学士学位和克莱蒙特研究生院德鲁克管理学院工商管理硕士学位。
Gayle Deflin has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since June 2021. Ms. Deflin has been the Chief Financial Officer of LBMB, Inc. since 2014, and its subsidiaries Plasticolor Molded Products, Inc. and Chroma Graphics, Inc., both of which are automotive accessory manufacturers and distributors, since 2006. Prior to 2006, Ms. Deflin was at Apria Healthcare, a provider of home respiratory services from 2004 to 2006 as Vice President of Strategic Planning and Budgeting and Vice President of Billing Center Operations. From 2003 to 2004 she served as President and Chief Executive Officer of Ionian Technologies, a diagnostic start up with biotechnology developed at the Keck Graduate Institute of Applied Life Sciences. Ms. Deflin worked in various positions at International Medication Systems Limited, including as its President, from 1989 until it was sold to Amphastar in 1998, and continued with Celltech Pharmaceuticals, the former owner of International Medication Systems, Limited, as President of MD Pharmaceuticals from 1996 to 2002 and Senior Vice President, Business Support Services of Celltech Pharmaceuticals from 2000 to 2002. Ms. Deflin holds a B.S. in Business Administration (Accounting and MIS) from Bowling Green State University and an M.B.A from the Drucker School of Management at Claremont Graduate University. - Gayle DeFlin自2021年6月起担任Amphastar Pharmaceuticals, Inc.董事会成员。Deflin女士自2014年起担任LBMB，Inc.及其子公司Plasticolor Molded Products，Inc.和Chroma Graphics，Inc.的首席财务官，这两家公司均为汽车配件制造商和分销商，自2006年起担任该公司的职务。在2006年之前，DeFlin女士曾于2004年至2006年在家庭呼吸服务提供商Apria Healthcare任职，担任战略规划和预算副总裁以及计费中心运营副总裁。从2003年到2004年，她担任Ionian Technologies的总裁兼首席执行官，这是一家在凯克应用生命科学研究所开发的生物技术诊断初创公司。Deflin女士于1989年在International Medication Systems Limited担任多个职位，包括担任总裁，直到该公司于1998年被出售给Amphastar。她于1996年至2002年继续在International Medication Systems，Limited的前所有者Celltech Pharmaceuticals担任MD Pharmaceuticals总裁，并于2000年至2002年担任Celltech Pharmaceuticals业务支持服务高级副总裁。Deflin女士拥有鲍灵格林州立大学工商管理（会计学和管理信息系统）学士学位和克莱蒙特研究生院德鲁克管理学院工商管理硕士学位。
- Gayle Deflin has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since June 2021. Ms. Deflin has been the Chief Financial Officer of LBMB, Inc. since 2014, and its subsidiaries Plasticolor Molded Products, Inc. and Chroma Graphics, Inc., both of which are automotive accessory manufacturers and distributors, since 2006. Prior to 2006, Ms. Deflin was at Apria Healthcare, a provider of home respiratory services from 2004 to 2006 as Vice President of Strategic Planning and Budgeting and Vice President of Billing Center Operations. From 2003 to 2004 she served as President and Chief Executive Officer of Ionian Technologies, a diagnostic start up with biotechnology developed at the Keck Graduate Institute of Applied Life Sciences. Ms. Deflin worked in various positions at International Medication Systems Limited, including as its President, from 1989 until it was sold to Amphastar in 1998, and continued with Celltech Pharmaceuticals, the former owner of International Medication Systems, Limited, as President of MD Pharmaceuticals from 1996 to 2002 and Senior Vice President, Business Support Services of Celltech Pharmaceuticals from 2000 to 2002. Ms. Deflin holds a B.S. in Business Administration (Accounting and MIS) from Bowling Green State University and an M.B.A from the Drucker School of Management at Claremont Graduate University.
- Richard Prins
-
Richard Prins自2012年起担任Igc Pharma公司董事长、审计委员会主席和薪酬委员会主席，自2007年5月起担任独立董事。1996年3月至2008年，他担任Ferris, Baker Watts, Incorporated （FBW）的投资银行总监。他曾担任加拿大皇家银行（RBC）的顾问，直到2009年1月。Prins先生目前在另一个董事会任职，在非营利组织advance Native Missions担任全职志愿者，并且是一名私人投资者。2003年2月以来，他一直担任Amphastar Pharmaceuticals, Inc.的董事。他持有Colgate University的学士学位和Oral Roberts University的工商管理硕士学位。
Richard Prins has served as Amphastar Pharmaceuticals, Inc.'s lead independent director since April 2019 and as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since February 2002. Since 2008, Mr. Prins has been a private investor and currently serves as lead investor and Chairman of EPH4, LLC. He is also involved in various charitable organizations. Mr. Prins served in various volunteer roles at Advancing Native Missions since 2004 including as a board member, Head of Operations and Stewardship, and as interim CEO. He has also served as a director of IGC Pharma, Inc., a biopharmaceutical company, since 2007, and as chairman of its board since 2012. Mr. Prins was the Director of Investment Banking for FBW, from 1996 until June 2008 when FBW was acquired by Royal Bank of Canada. Prior to FBW, Mr. Prins was a Managing Director from July 1988 to April 1996 at Crestar Bank (now Truist Bank) in charge of mergers and acquisitions. Mr. Prins began his career in 1983 as the Assistant to the Chairman of the leverage buyout company, Tuscarora Corp., where he held various positions until July 1988. Mr. Prins received a B.A. in liberal arts from Colgate University and an M.B.A. from Oral Roberts University. - Richard Prins自2012年起担任Igc Pharma公司董事长、审计委员会主席和薪酬委员会主席，自2007年5月起担任独立董事。1996年3月至2008年，他担任Ferris, Baker Watts, Incorporated （FBW）的投资银行总监。他曾担任加拿大皇家银行（RBC）的顾问，直到2009年1月。Prins先生目前在另一个董事会任职，在非营利组织advance Native Missions担任全职志愿者，并且是一名私人投资者。2003年2月以来，他一直担任Amphastar Pharmaceuticals, Inc.的董事。他持有Colgate University的学士学位和Oral Roberts University的工商管理硕士学位。
- Richard Prins has served as Amphastar Pharmaceuticals, Inc.'s lead independent director since April 2019 and as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since February 2002. Since 2008, Mr. Prins has been a private investor and currently serves as lead investor and Chairman of EPH4, LLC. He is also involved in various charitable organizations. Mr. Prins served in various volunteer roles at Advancing Native Missions since 2004 including as a board member, Head of Operations and Stewardship, and as interim CEO. He has also served as a director of IGC Pharma, Inc., a biopharmaceutical company, since 2007, and as chairman of its board since 2012. Mr. Prins was the Director of Investment Banking for FBW, from 1996 until June 2008 when FBW was acquired by Royal Bank of Canada. Prior to FBW, Mr. Prins was a Managing Director from July 1988 to April 1996 at Crestar Bank (now Truist Bank) in charge of mergers and acquisitions. Mr. Prins began his career in 1983 as the Assistant to the Chairman of the leverage buyout company, Tuscarora Corp., where he held various positions until July 1988. Mr. Prins received a B.A. in liberal arts from Colgate University and an M.B.A. from Oral Roberts University.
- Jack Yongfeng Zhang
-
Jack Yongfeng Zhang，于1996年到2013年6月担任首席执行官和董事会的一员和总裁。自2005年以来他还担任过首席科学官。他成立了应用物理和化学实验室公司，是全方位服务的化学分析实验室。1989年5月，他担任总裁职务直到2002年10月。他是几个美国和外国专利的发明者。他在纽约州立大学石溪分校获得了化学博士学位，是一篇加州理工学院的博士研究员。
Jack Yongfeng Zhang co founded Amphastar Pharmaceuticals, Inc.'s Company in 1996 has served as Amphastar Pharmaceuticals, Inc.'s Chief Executive Officer and a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since Amphastar Pharmaceuticals, Inc.'s inception and was re appointed as Amphastar Pharmaceuticals, Inc.'s President in April 2020, after serving as President from 1996 until June 2013. Dr. Zhang has also served as Amphastar Pharmaceuticals, Inc.'s Chief Scientific Officer since 2005. Dr. Zhang co founded APCL, a full service chemical analytical laboratory, in May 1989, where he held the position of President until October 2002. Dr. Zhang is named as the inventor on several U.S. and foreign patents. He received a Ph.D. in chemistry from the State University of New York at Stony Brook and was a Post Doctoral Research Associate at the California Institute of Technology. - Jack Yongfeng Zhang，于1996年到2013年6月担任首席执行官和董事会的一员和总裁。自2005年以来他还担任过首席科学官。他成立了应用物理和化学实验室公司，是全方位服务的化学分析实验室。1989年5月，他担任总裁职务直到2002年10月。他是几个美国和外国专利的发明者。他在纽约州立大学石溪分校获得了化学博士学位，是一篇加州理工学院的博士研究员。
- Jack Yongfeng Zhang co founded Amphastar Pharmaceuticals, Inc.'s Company in 1996 has served as Amphastar Pharmaceuticals, Inc.'s Chief Executive Officer and a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since Amphastar Pharmaceuticals, Inc.'s inception and was re appointed as Amphastar Pharmaceuticals, Inc.'s President in April 2020, after serving as President from 1996 until June 2013. Dr. Zhang has also served as Amphastar Pharmaceuticals, Inc.'s Chief Scientific Officer since 2005. Dr. Zhang co founded APCL, a full service chemical analytical laboratory, in May 1989, where he held the position of President until October 2002. Dr. Zhang is named as the inventor on several U.S. and foreign patents. He received a Ph.D. in chemistry from the State University of New York at Stony Brook and was a Post Doctoral Research Associate at the California Institute of Technology.
- Mary Ziping Luo
-
Mary Ziping Luo，她于1996年担任首席运营官和董事会主席，从1997年到2004年4月担任秘书。自2005年以来她还担任首席科学家。她1989年5月创立APCL，一直在首席运营官的位置。她是加州州立理工大学名誉化学教授，是美国和外国几个专利的发明者。她获得了普林斯顿大学的化学博士学位，是加州理工学院的博士研究员。
Mary Ziping Luo co founded Amphastar Pharmaceuticals, Inc.'s Company in 1996 and has served as Amphastar Pharmaceuticals, Inc.'s Chief Operating Officer and chairman of Amphastar Pharmaceuticals, Inc.'s Board of Directors since Amphastar Pharmaceuticals, Inc.'s inception and as Corporate Secretary from 1997 to April 2004. Dr. Luo has also served as Amphastar Pharmaceuticals, Inc.'s Chief Scientist since 2005. Dr. Luo co founded Applied Physics & Chemistry Laboratories, Inc., or APCL, a full service chemical analytical laboratory, in May 1989, where she held the position of Chief Operating Officer. Dr. Luo is a professor emeritus of chemistry at California State Polytechnic University, Pomona and is named as the inventor on several U.S. and foreign patents. Dr. Luo received a Ph.D. in chemistry from Princeton University and was a Post Doctoral Research Associate at the California Institute of Technology. - Mary Ziping Luo，她于1996年担任首席运营官和董事会主席，从1997年到2004年4月担任秘书。自2005年以来她还担任首席科学家。她1989年5月创立APCL，一直在首席运营官的位置。她是加州州立理工大学名誉化学教授，是美国和外国几个专利的发明者。她获得了普林斯顿大学的化学博士学位，是加州理工学院的博士研究员。
- Mary Ziping Luo co founded Amphastar Pharmaceuticals, Inc.'s Company in 1996 and has served as Amphastar Pharmaceuticals, Inc.'s Chief Operating Officer and chairman of Amphastar Pharmaceuticals, Inc.'s Board of Directors since Amphastar Pharmaceuticals, Inc.'s inception and as Corporate Secretary from 1997 to April 2004. Dr. Luo has also served as Amphastar Pharmaceuticals, Inc.'s Chief Scientist since 2005. Dr. Luo co founded Applied Physics & Chemistry Laboratories, Inc., or APCL, a full service chemical analytical laboratory, in May 1989, where she held the position of Chief Operating Officer. Dr. Luo is a professor emeritus of chemistry at California State Polytechnic University, Pomona and is named as the inventor on several U.S. and foreign patents. Dr. Luo received a Ph.D. in chemistry from Princeton University and was a Post Doctoral Research Associate at the California Institute of Technology.
- William J. Peters
-
William J. Peters，自2014年4月起担任首席财务官、高级副总裁兼财务主管，自2016年3月起担任International Medication Systems， LimitedAmphastar Pharmaceutical的子公司总裁。2013年8月至2014年4月，Peters先生担任high - tech pharmaceutical Co., Inc. （high - tech）的执行副总裁兼首席财务官；2004年5月至2013年8月，担任high - tech的副总裁兼首席财务官。从2003年9月到2004年5月，他担任high - tech公司的企业发展副总裁。从2001年到2003年，他担任Merck & Co., Inc.的Medco Health Solution子公司的财务评估总监；从1998年到2001年，担任Merck & Co.的企业财务分析和药物经济学经理。在Merck & Co的7年职业生涯中，他还担任财务规划和分析经理。他的职业生涯始于通用电气航空航天部门的财务管理项目，后来担任财务分析和内部审计职位。他获得The Wharton School of Business，Pennsylvania大学的工商管理硕士学位，以及Bucknell大学的工商管理学士学位。
William J. Peters has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since August 2022, Amphastar Pharmaceuticals, Inc.'s Chief Financial Officer, Executive Vice President and Treasurer since May 2021 and was Amphastar Pharmaceuticals, Inc.'s Chief Financial Officer and Treasurer since April 2014, and as Amphastar Pharmaceuticals, Inc.'s President of International Medication Systems, Limited (a wholly owned subsidiary of Amphastar) since March 2016. Mr. Peters previously served as Chief Financial Officer of Hi Tech Pharmacal Co., Inc., or Hi Tech, from May 2004 to April 2014. From September 2003 to May 2004 he was Vice President of Corporate Development at Hi Tech. From 2001 to 2003 Mr. Peters was the Director, Financial Evaluations for the Medco Health Solution subsidiary of Merck & Co., Inc., or Merck & Co., and during his seven year career at Merck & Co., he also served in several positions of increasing responsibility. He began his career in General Electric's Financial Management Program, at its Aerospace division, where he later held positions in financial analysis and internal auditing. He earned an M.B.A. from The Wharton School of Business, of the University of Pennsylvania and a B.S. in Business Administration from Bucknell University. - William J. Peters，自2014年4月起担任首席财务官、高级副总裁兼财务主管，自2016年3月起担任International Medication Systems， LimitedAmphastar Pharmaceutical的子公司总裁。2013年8月至2014年4月，Peters先生担任high - tech pharmaceutical Co., Inc. （high - tech）的执行副总裁兼首席财务官；2004年5月至2013年8月，担任high - tech的副总裁兼首席财务官。从2003年9月到2004年5月，他担任high - tech公司的企业发展副总裁。从2001年到2003年，他担任Merck & Co., Inc.的Medco Health Solution子公司的财务评估总监；从1998年到2001年，担任Merck & Co.的企业财务分析和药物经济学经理。在Merck & Co的7年职业生涯中，他还担任财务规划和分析经理。他的职业生涯始于通用电气航空航天部门的财务管理项目，后来担任财务分析和内部审计职位。他获得The Wharton School of Business，Pennsylvania大学的工商管理硕士学位，以及Bucknell大学的工商管理学士学位。
- William J. Peters has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since August 2022, Amphastar Pharmaceuticals, Inc.'s Chief Financial Officer, Executive Vice President and Treasurer since May 2021 and was Amphastar Pharmaceuticals, Inc.'s Chief Financial Officer and Treasurer since April 2014, and as Amphastar Pharmaceuticals, Inc.'s President of International Medication Systems, Limited (a wholly owned subsidiary of Amphastar) since March 2016. Mr. Peters previously served as Chief Financial Officer of Hi Tech Pharmacal Co., Inc., or Hi Tech, from May 2004 to April 2014. From September 2003 to May 2004 he was Vice President of Corporate Development at Hi Tech. From 2001 to 2003 Mr. Peters was the Director, Financial Evaluations for the Medco Health Solution subsidiary of Merck & Co., Inc., or Merck & Co., and during his seven year career at Merck & Co., he also served in several positions of increasing responsibility. He began his career in General Electric's Financial Management Program, at its Aerospace division, where he later held positions in financial analysis and internal auditing. He earned an M.B.A. from The Wharton School of Business, of the University of Pennsylvania and a B.S. in Business Administration from Bucknell University.
- Diane G. Gerst
-
Diane G. Gerst，2014年3月以来曾担任ANP总裁和2012年8月以来担任Amphastar Pharmaceuticals, Inc.质量保证的高级副总裁。她从2003年8月担任公司质量保证副总裁，直到她晋升为高级副总裁。成为质量保证的副总裁之前，从2001年6月到2002年7月她是Amphastar Pharmaceuticals, Inc.监管事务副总裁。她之前在监管和质量担任各种管理职位，包括Braun-McGaw八年和在IMS七年。她1982年在伯克利拥有加州大学学士学位。
Diane G. Gerst has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since June 2019. She previously served as Amphastar Pharmaceuticals, Inc.'s Executive Vice President of Quality Assurance and Regulatory Affairs from June 2015 until February 2018 and also served as the President of Amphastar Nanjing Pharmaceuticals Inc., one of Amphastar Pharmaceuticals, Inc.'s subsidiaries,from March 2014 until February 2018. From August 2013 to June 2015, Ms. Gerst served as Amphastar Pharmaceuticals, Inc.'s Corporate Senior Vice President of Quality Assurance. She served as Corporate Vice President of Quality Assurance from August 2003 until her promotion to Senior Vice President in August 2013 and as Vice President of Regulatory Affairs from June 2001 to July 2002. Prior to joining Amphastar Pharmaceuticals, Inc., Ms. Gerst held various management level positions in regulatory and quality including eight years at Braun McGaw and seven years at IMS. Ms. Gerst received a B.A. from the University of California, Berkeley. - Diane G. Gerst，2014年3月以来曾担任ANP总裁和2012年8月以来担任Amphastar Pharmaceuticals, Inc.质量保证的高级副总裁。她从2003年8月担任公司质量保证副总裁，直到她晋升为高级副总裁。成为质量保证的副总裁之前，从2001年6月到2002年7月她是Amphastar Pharmaceuticals, Inc.监管事务副总裁。她之前在监管和质量担任各种管理职位，包括Braun-McGaw八年和在IMS七年。她1982年在伯克利拥有加州大学学士学位。
- Diane G. Gerst has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since June 2019. She previously served as Amphastar Pharmaceuticals, Inc.'s Executive Vice President of Quality Assurance and Regulatory Affairs from June 2015 until February 2018 and also served as the President of Amphastar Nanjing Pharmaceuticals Inc., one of Amphastar Pharmaceuticals, Inc.'s subsidiaries,from March 2014 until February 2018. From August 2013 to June 2015, Ms. Gerst served as Amphastar Pharmaceuticals, Inc.'s Corporate Senior Vice President of Quality Assurance. She served as Corporate Vice President of Quality Assurance from August 2003 until her promotion to Senior Vice President in August 2013 and as Vice President of Regulatory Affairs from June 2001 to July 2002. Prior to joining Amphastar Pharmaceuticals, Inc., Ms. Gerst held various management level positions in regulatory and quality including eight years at Braun McGaw and seven years at IMS. Ms. Gerst received a B.A. from the University of California, Berkeley.
- Howard Lee
-
Howard Lee，2007年8月以来曾担任董事会成员。他之前从1998年到2002年担任子公司IMS的董事会成员，从2002年到2004年在董事会。2012年3月以来到目前一直是CID集团大中华区著名投资集团合伙人。从2009年到2010年他是UniMed风险管理公司首席投资官。2009年7月加入UniMed之前，从2006年7月到2009年6月他是Silver生物技术管理公司一名董事总经理。他从2000年到2006年担任CDIB美国生物技术投资有限公司总裁兼首席执行官，于1995年10月到2006年6月担任中国工业发展银行的副总裁。他还是台湾生物科技发展中心主任。他在台湾Fu-Jen大学获得了位运筹学理学学位，分别于1988年和1990年从洛杉矶的南加州大学化学获得硕士学位和博士学位，在南加州大学Loker Hydrocarbon的研究所完成了博士后研究。
Howard Lee has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since August 2007. He previously served as a member of the board of Amphastar Pharmaceuticals, Inc.'s subsidiary, IMS, from 1998 to 2002 and on Amphastar Pharmaceuticals, Inc.'s Board of Directors from 2002 to 2004. Dr. Lee has served as the Chairman and Chief Executive Officer of TAHO Pharmaceuticals, Ltd., a drug development company with a transepithelial technology platform based in Taiwan since January 2020. Previously, Dr. Lee was the partner at the CID Group, a prominent investment group in the greater China area from March 2012 to January 2020. From 2009 to 2010 he was the Chief Investment Officer at UniMed Venture Management Inc., a biotech venture capital firm. Prior to joining UniMed in July 2009, he was a Managing Director at Silver Biotech Management, Inc. from July 2006 to June 2009. Dr. Lee served as President and CEO of CDIB Biotech USA Investment Co. Ltd. from 2000 to 2006 and as Vice President of China Development Industrial Bank, an investment bank in Taiwan, from October 1995 to June 2006. Dr. Lee earned his B.Sc. at Fu Jen University (Taiwan), his M.Sc. and Ph.D. degrees in chemistry from the University of Southern California in Los Angeles and completed his postdoctoral research at the Loker Hydrocarbon Research Institute of the University of Southern California. - Howard Lee，2007年8月以来曾担任董事会成员。他之前从1998年到2002年担任子公司IMS的董事会成员，从2002年到2004年在董事会。2012年3月以来到目前一直是CID集团大中华区著名投资集团合伙人。从2009年到2010年他是UniMed风险管理公司首席投资官。2009年7月加入UniMed之前，从2006年7月到2009年6月他是Silver生物技术管理公司一名董事总经理。他从2000年到2006年担任CDIB美国生物技术投资有限公司总裁兼首席执行官，于1995年10月到2006年6月担任中国工业发展银行的副总裁。他还是台湾生物科技发展中心主任。他在台湾Fu-Jen大学获得了位运筹学理学学位，分别于1988年和1990年从洛杉矶的南加州大学化学获得硕士学位和博士学位，在南加州大学Loker Hydrocarbon的研究所完成了博士后研究。
- Howard Lee has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since August 2007. He previously served as a member of the board of Amphastar Pharmaceuticals, Inc.'s subsidiary, IMS, from 1998 to 2002 and on Amphastar Pharmaceuticals, Inc.'s Board of Directors from 2002 to 2004. Dr. Lee has served as the Chairman and Chief Executive Officer of TAHO Pharmaceuticals, Ltd., a drug development company with a transepithelial technology platform based in Taiwan since January 2020. Previously, Dr. Lee was the partner at the CID Group, a prominent investment group in the greater China area from March 2012 to January 2020. From 2009 to 2010 he was the Chief Investment Officer at UniMed Venture Management Inc., a biotech venture capital firm. Prior to joining UniMed in July 2009, he was a Managing Director at Silver Biotech Management, Inc. from July 2006 to June 2009. Dr. Lee served as President and CEO of CDIB Biotech USA Investment Co. Ltd. from 2000 to 2006 and as Vice President of China Development Industrial Bank, an investment bank in Taiwan, from October 1995 to June 2006. Dr. Lee earned his B.Sc. at Fu Jen University (Taiwan), his M.Sc. and Ph.D. degrees in chemistry from the University of Southern California in Los Angeles and completed his postdoctoral research at the Loker Hydrocarbon Research Institute of the University of Southern California.
- Michael A. Zasloff
-
Michael A. Zasloff，他是医学博士，2005年10月以来曾担任董事会的成员。他自2002年以来一直是乔治敦大学医学院外科和儿科教授，从2002年到2004年也研究和转化科学院长。他2004年至2007年担任Baker Watts公司Ferris生命科学的副总裁和高级分析师。从1992年到2001年他担任蛙皮素制药公司执行副总裁兼副主席，他创办的生物制药公司。他从1988年到1992年担任宾夕法尼亚大学医学院儿科和遗传学教授和在费城儿童医院人类遗传学与分子生物学的首席。他从1982年到1988年是美国国立儿童健康与人类发展研究院人类遗传学分支的首席。他持有哥伦比亚大学生物化学学士学位，拥有医学博士，纽约大学医学院博士学位。他是40多个专利的发明者。
Michael A. Zasloff has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since October 2005 and previously served as Amphastar Pharmaceuticals, Inc.'s lead independent director from January 2016 to April 2019. Dr. Zasloff has been the Professor of Surgery and Pediatrics at the Georgetown University School of Medicine since 2002, and currently serves as Scientific Director of the MedStar – Georgetown Transplant Institute. In 2016 Dr. Zasloff founded Enterin, Inc., a biopharmaceutical company developing therapeutics for Parkinson's disease and other neurodegenerative disorders, where he serves as Director and Chief Scientific Officer. In 2023, Dr. Zasloff founded BAZ Therapeutics, a biopharmaceutical company developing therapeutics directed at diseases of aging, where he serves as Director. Dr. Zasloff served as the Dean of Research and Translational Science from 2002 until 2004. Between 2004 and 2007, Dr. Zasloff served as Vice President and Senior Analyst (Life Sciences) at Ferris, Baker Watts, Inc., or FBW. From 1992 to 2001 Dr. Zasloff served as Executive Vice President and Vice Chairman of Magainin Pharmaceuticals Inc., a biopharmaceutical company which he founded. From 1988 until 1992, Dr. Zasloff served as the Charles E.H. Upham Professor in the Department of Pediatrics and Genetics at the University of Pennsylvania School of Medicine, and Chief, Division of Human Genetics and Molecular Biology at The Children's Hospital of Philadelphia. From 1982 until 1988, Dr. Zasloff was Chief of the Human Genetics Branch at the National Institutes of Child Health and Human Development, National Institutes of Health. Dr. Zasloff received a B.A. from Columbia College in biochemistry and holds an M.D., Ph.D. from the New York University School of Medicine. - Michael A. Zasloff，他是医学博士，2005年10月以来曾担任董事会的成员。他自2002年以来一直是乔治敦大学医学院外科和儿科教授，从2002年到2004年也研究和转化科学院长。他2004年至2007年担任Baker Watts公司Ferris生命科学的副总裁和高级分析师。从1992年到2001年他担任蛙皮素制药公司执行副总裁兼副主席，他创办的生物制药公司。他从1988年到1992年担任宾夕法尼亚大学医学院儿科和遗传学教授和在费城儿童医院人类遗传学与分子生物学的首席。他从1982年到1988年是美国国立儿童健康与人类发展研究院人类遗传学分支的首席。他持有哥伦比亚大学生物化学学士学位，拥有医学博士，纽约大学医学院博士学位。他是40多个专利的发明者。
- Michael A. Zasloff has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since October 2005 and previously served as Amphastar Pharmaceuticals, Inc.'s lead independent director from January 2016 to April 2019. Dr. Zasloff has been the Professor of Surgery and Pediatrics at the Georgetown University School of Medicine since 2002, and currently serves as Scientific Director of the MedStar – Georgetown Transplant Institute. In 2016 Dr. Zasloff founded Enterin, Inc., a biopharmaceutical company developing therapeutics for Parkinson's disease and other neurodegenerative disorders, where he serves as Director and Chief Scientific Officer. In 2023, Dr. Zasloff founded BAZ Therapeutics, a biopharmaceutical company developing therapeutics directed at diseases of aging, where he serves as Director. Dr. Zasloff served as the Dean of Research and Translational Science from 2002 until 2004. Between 2004 and 2007, Dr. Zasloff served as Vice President and Senior Analyst (Life Sciences) at Ferris, Baker Watts, Inc., or FBW. From 1992 to 2001 Dr. Zasloff served as Executive Vice President and Vice Chairman of Magainin Pharmaceuticals Inc., a biopharmaceutical company which he founded. From 1988 until 1992, Dr. Zasloff served as the Charles E.H. Upham Professor in the Department of Pediatrics and Genetics at the University of Pennsylvania School of Medicine, and Chief, Division of Human Genetics and Molecular Biology at The Children's Hospital of Philadelphia. From 1982 until 1988, Dr. Zasloff was Chief of the Human Genetics Branch at the National Institutes of Child Health and Human Development, National Institutes of Health. Dr. Zasloff received a B.A. from Columbia College in biochemistry and holds an M.D., Ph.D. from the New York University School of Medicine.
- Floyd F. Petersen
-
Floyd F. Petersen，2004年8月以来担任董事会的成员。从1986年到现在，他一直是Loma Linda大学公共卫生学校的医学和护理生物统计学副教授。他从1990年到2010年担任洛玛连达大学健康研究咨询集团董事，致力于为医疗研究设计和数据分析。他从1990年到2010年是Loma Linda（加州市议会）的成员，担任从1996年到2006年Loma Linda市长。 他目前是Vtrans董事会副主席，一个非盈利的准政府机构。他获得Loma Linda大学的M.P.H，关注生物统计学和健康管理。
Floyd F. Petersen has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since August 2004. From 1986 until his retirement in August 2014, Mr. Petersen served as an Assistant Professor of Biostatistics at Loma Linda University Schools of Public Health, Medicine, and Nursing. From 1990 to 2010, Mr. Petersen served as Director of the Loma Linda University Health Research Consulting Group, which consults on health research study design and data analysis. Mr. Petersen was a member of the Loma Linda, California City Council from 1990 to 2010 and served as the Mayor of Loma Linda from 1996 to 2006. Mr. Petersen earned an M.P.H. from Loma Linda University with concentrations in Biostatistics and Health Administration. Mr. Petersen is not standing for re election but will continue to serve as a member of Amphastar Pharmaceuticals, Inc.'s board of directors until the expiration of his current term ending on the date of the Annual Meeting. - Floyd F. Petersen，2004年8月以来担任董事会的成员。从1986年到现在，他一直是Loma Linda大学公共卫生学校的医学和护理生物统计学副教授。他从1990年到2010年担任洛玛连达大学健康研究咨询集团董事，致力于为医疗研究设计和数据分析。他从1990年到2010年是Loma Linda（加州市议会）的成员，担任从1996年到2006年Loma Linda市长。 他目前是Vtrans董事会副主席，一个非盈利的准政府机构。他获得Loma Linda大学的M.P.H，关注生物统计学和健康管理。
- Floyd F. Petersen has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since August 2004. From 1986 until his retirement in August 2014, Mr. Petersen served as an Assistant Professor of Biostatistics at Loma Linda University Schools of Public Health, Medicine, and Nursing. From 1990 to 2010, Mr. Petersen served as Director of the Loma Linda University Health Research Consulting Group, which consults on health research study design and data analysis. Mr. Petersen was a member of the Loma Linda, California City Council from 1990 to 2010 and served as the Mayor of Loma Linda from 1996 to 2006. Mr. Petersen earned an M.P.H. from Loma Linda University with concentrations in Biostatistics and Health Administration. Mr. Petersen is not standing for re election but will continue to serve as a member of Amphastar Pharmaceuticals, Inc.'s board of directors until the expiration of his current term ending on the date of the Annual Meeting.
高管简历
中英对照 | 中文 | 英文- Rong Zhou
Rong Zhou，曾担任多个行政职务，最近的一次是自2015年6月起担任生产中心执行副总裁。自2014年3月起担任Armstrong Pharmaceuticals，Inc.总裁。Amphastar制药的子公司总裁，自2012年8月起担任科学事务高级副总裁。Zhou先生自2001年10月起担任公司科学事务副总裁，直至晋升为高级副总裁。Zhou先生获得福州大学化学工程学士学位和扬斯敦州立大学硕士学位。
Rong Zhou has served in various executive roles since joining in October 1998 most recently as Executive Vice President of Production Center since June 2015 President of Armstrong Pharmaceuticals, Inc. Amphastar Pharmaceutical's subsidiary company since March 2014 and as Senior Vice President of Scientific Affairs since August 2012. Mr. Zhou served as Corporate Vice President of Scientific Affairs from October 2001 until his promotion to Senior Vice President. Mr. Zhou received a B.S. in Chemical Engineering from the Fuzhou University and an M.S. from the Youngstown State University.- Rong Zhou，曾担任多个行政职务，最近的一次是自2015年6月起担任生产中心执行副总裁。自2014年3月起担任Armstrong Pharmaceuticals，Inc.总裁。Amphastar制药的子公司总裁，自2012年8月起担任科学事务高级副总裁。Zhou先生自2001年10月起担任公司科学事务副总裁，直至晋升为高级副总裁。Zhou先生获得福州大学化学工程学士学位和扬斯敦州立大学硕士学位。
- Rong Zhou has served in various executive roles since joining in October 1998 most recently as Executive Vice President of Production Center since June 2015 President of Armstrong Pharmaceuticals, Inc. Amphastar Pharmaceutical's subsidiary company since March 2014 and as Senior Vice President of Scientific Affairs since August 2012. Mr. Zhou served as Corporate Vice President of Scientific Affairs from October 2001 until his promotion to Senior Vice President. Mr. Zhou received a B.S. in Chemical Engineering from the Fuzhou University and an M.S. from the Youngstown State University.
- Jacob Liawatidewi
Jacob Liawatidewi自2022年8月起担任Amphastar Pharmaceuticals, Inc.董事会成员，自2020年5月起担任销售和营销执行副总裁兼公司行政中心执行副总裁，自2020年12月起担任Amphastar France Pharmaceuticals，S.A.S.（Amphastar的全资子公司）总裁，自2013年6月起担任公司秘书。Liawatidewi先生分别于2014年3月和2013年12月担任企业行政中心高级副总裁和销售与市场营销高级副总裁，直至晋升为执行副总裁。Liawatidewi先生自2012年8月起担任销售和营销副总裁，直至晋升为高级副总裁。2005年8月至2012年8月，Liawatidewi先生担任Amphastar Pharmaceuticals, Inc.的销售和市场营销副总裁。从1997年6月加入Amphastar Pharmaceuticals，Inc.到2005年8月，Liawatidewi先生曾在Amphastar Pharmaceuticals, Inc.的业务发展、销售和营销部门担任多个职务。Liawatidewi先生于1996年获得加州州立大学弗雷斯诺分校的生物学学士学位，2014年获得国立大学的工商管理硕士学位，2022年获得协和法学院的法学博士学位。
Jacob Liawatidewi has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since August 2022, Executive Vice President of Sales and Marketing and Executive Vice President of Corporate Administration Center since May 2020, President of Amphastar France Pharmaceuticals, S.A.S. (a wholly owned subsidiary of Amphastar) since December 2020, and Corporate Secretary since June 2013. Mr. Liawatidewi served as Senior Vice President of Corporate Administration Center and Senior Vice President of Sales and Marketing from March 2014 and December 2013, respectively, until his promotion to Executive Vice President. Mr. Liawatidewi served as Vice President of Sales and Marketing from August 2012 until his promotion to Senior Vice President. From August 2005 to August 2012, Mr. Liawatidewi was Amphastar Pharmaceuticals, Inc.'s Associate Vice President of Sales and Marketing. From joining Amphastar Pharmaceuticals, Inc. in June 1997 to August 2005, Mr. Liawatidewi held various roles in Amphastar Pharmaceuticals, Inc.'s business development, sales and marketing department. Mr. Liawatidewi received a B.S. in Biology from California State University of Fresno in 1996, an M.B.A. from National University in 2014, and an E.J.D. from Concord Law School in 2022.- Jacob Liawatidewi自2022年8月起担任Amphastar Pharmaceuticals, Inc.董事会成员，自2020年5月起担任销售和营销执行副总裁兼公司行政中心执行副总裁，自2020年12月起担任Amphastar France Pharmaceuticals，S.A.S.（Amphastar的全资子公司）总裁，自2013年6月起担任公司秘书。Liawatidewi先生分别于2014年3月和2013年12月担任企业行政中心高级副总裁和销售与市场营销高级副总裁，直至晋升为执行副总裁。Liawatidewi先生自2012年8月起担任销售和营销副总裁，直至晋升为高级副总裁。2005年8月至2012年8月，Liawatidewi先生担任Amphastar Pharmaceuticals, Inc.的销售和市场营销副总裁。从1997年6月加入Amphastar Pharmaceuticals，Inc.到2005年8月，Liawatidewi先生曾在Amphastar Pharmaceuticals, Inc.的业务发展、销售和营销部门担任多个职务。Liawatidewi先生于1996年获得加州州立大学弗雷斯诺分校的生物学学士学位，2014年获得国立大学的工商管理硕士学位，2022年获得协和法学院的法学博士学位。
- Jacob Liawatidewi has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since August 2022, Executive Vice President of Sales and Marketing and Executive Vice President of Corporate Administration Center since May 2020, President of Amphastar France Pharmaceuticals, S.A.S. (a wholly owned subsidiary of Amphastar) since December 2020, and Corporate Secretary since June 2013. Mr. Liawatidewi served as Senior Vice President of Corporate Administration Center and Senior Vice President of Sales and Marketing from March 2014 and December 2013, respectively, until his promotion to Executive Vice President. Mr. Liawatidewi served as Vice President of Sales and Marketing from August 2012 until his promotion to Senior Vice President. From August 2005 to August 2012, Mr. Liawatidewi was Amphastar Pharmaceuticals, Inc.'s Associate Vice President of Sales and Marketing. From joining Amphastar Pharmaceuticals, Inc. in June 1997 to August 2005, Mr. Liawatidewi held various roles in Amphastar Pharmaceuticals, Inc.'s business development, sales and marketing department. Mr. Liawatidewi received a B.S. in Biology from California State University of Fresno in 1996, an M.B.A. from National University in 2014, and an E.J.D. from Concord Law School in 2022.
- Jack Yongfeng Zhang
Jack Yongfeng Zhang，于1996年到2013年6月担任首席执行官和董事会的一员和总裁。自2005年以来他还担任过首席科学官。他成立了应用物理和化学实验室公司，是全方位服务的化学分析实验室。1989年5月，他担任总裁职务直到2002年10月。他是几个美国和外国专利的发明者。他在纽约州立大学石溪分校获得了化学博士学位，是一篇加州理工学院的博士研究员。
Jack Yongfeng Zhang co founded Amphastar Pharmaceuticals, Inc.'s Company in 1996 has served as Amphastar Pharmaceuticals, Inc.'s Chief Executive Officer and a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since Amphastar Pharmaceuticals, Inc.'s inception and was re appointed as Amphastar Pharmaceuticals, Inc.'s President in April 2020, after serving as President from 1996 until June 2013. Dr. Zhang has also served as Amphastar Pharmaceuticals, Inc.'s Chief Scientific Officer since 2005. Dr. Zhang co founded APCL, a full service chemical analytical laboratory, in May 1989, where he held the position of President until October 2002. Dr. Zhang is named as the inventor on several U.S. and foreign patents. He received a Ph.D. in chemistry from the State University of New York at Stony Brook and was a Post Doctoral Research Associate at the California Institute of Technology.- Jack Yongfeng Zhang，于1996年到2013年6月担任首席执行官和董事会的一员和总裁。自2005年以来他还担任过首席科学官。他成立了应用物理和化学实验室公司，是全方位服务的化学分析实验室。1989年5月，他担任总裁职务直到2002年10月。他是几个美国和外国专利的发明者。他在纽约州立大学石溪分校获得了化学博士学位，是一篇加州理工学院的博士研究员。
- Jack Yongfeng Zhang co founded Amphastar Pharmaceuticals, Inc.'s Company in 1996 has served as Amphastar Pharmaceuticals, Inc.'s Chief Executive Officer and a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since Amphastar Pharmaceuticals, Inc.'s inception and was re appointed as Amphastar Pharmaceuticals, Inc.'s President in April 2020, after serving as President from 1996 until June 2013. Dr. Zhang has also served as Amphastar Pharmaceuticals, Inc.'s Chief Scientific Officer since 2005. Dr. Zhang co founded APCL, a full service chemical analytical laboratory, in May 1989, where he held the position of President until October 2002. Dr. Zhang is named as the inventor on several U.S. and foreign patents. He received a Ph.D. in chemistry from the State University of New York at Stony Brook and was a Post Doctoral Research Associate at the California Institute of Technology.
- Mary Ziping Luo
Mary Ziping Luo，她于1996年担任首席运营官和董事会主席，从1997年到2004年4月担任秘书。自2005年以来她还担任首席科学家。她1989年5月创立APCL，一直在首席运营官的位置。她是加州州立理工大学名誉化学教授，是美国和外国几个专利的发明者。她获得了普林斯顿大学的化学博士学位，是加州理工学院的博士研究员。
Mary Ziping Luo co founded Amphastar Pharmaceuticals, Inc.'s Company in 1996 and has served as Amphastar Pharmaceuticals, Inc.'s Chief Operating Officer and chairman of Amphastar Pharmaceuticals, Inc.'s Board of Directors since Amphastar Pharmaceuticals, Inc.'s inception and as Corporate Secretary from 1997 to April 2004. Dr. Luo has also served as Amphastar Pharmaceuticals, Inc.'s Chief Scientist since 2005. Dr. Luo co founded Applied Physics & Chemistry Laboratories, Inc., or APCL, a full service chemical analytical laboratory, in May 1989, where she held the position of Chief Operating Officer. Dr. Luo is a professor emeritus of chemistry at California State Polytechnic University, Pomona and is named as the inventor on several U.S. and foreign patents. Dr. Luo received a Ph.D. in chemistry from Princeton University and was a Post Doctoral Research Associate at the California Institute of Technology.- Mary Ziping Luo，她于1996年担任首席运营官和董事会主席，从1997年到2004年4月担任秘书。自2005年以来她还担任首席科学家。她1989年5月创立APCL，一直在首席运营官的位置。她是加州州立理工大学名誉化学教授，是美国和外国几个专利的发明者。她获得了普林斯顿大学的化学博士学位，是加州理工学院的博士研究员。
- Mary Ziping Luo co founded Amphastar Pharmaceuticals, Inc.'s Company in 1996 and has served as Amphastar Pharmaceuticals, Inc.'s Chief Operating Officer and chairman of Amphastar Pharmaceuticals, Inc.'s Board of Directors since Amphastar Pharmaceuticals, Inc.'s inception and as Corporate Secretary from 1997 to April 2004. Dr. Luo has also served as Amphastar Pharmaceuticals, Inc.'s Chief Scientist since 2005. Dr. Luo co founded Applied Physics & Chemistry Laboratories, Inc., or APCL, a full service chemical analytical laboratory, in May 1989, where she held the position of Chief Operating Officer. Dr. Luo is a professor emeritus of chemistry at California State Polytechnic University, Pomona and is named as the inventor on several U.S. and foreign patents. Dr. Luo received a Ph.D. in chemistry from Princeton University and was a Post Doctoral Research Associate at the California Institute of Technology.
- William J. Peters
William J. Peters，自2014年4月起担任首席财务官、高级副总裁兼财务主管，自2016年3月起担任International Medication Systems， LimitedAmphastar Pharmaceutical的子公司总裁。2013年8月至2014年4月，Peters先生担任high - tech pharmaceutical Co., Inc. （high - tech）的执行副总裁兼首席财务官；2004年5月至2013年8月，担任high - tech的副总裁兼首席财务官。从2003年9月到2004年5月，他担任high - tech公司的企业发展副总裁。从2001年到2003年，他担任Merck & Co., Inc.的Medco Health Solution子公司的财务评估总监；从1998年到2001年，担任Merck & Co.的企业财务分析和药物经济学经理。在Merck & Co的7年职业生涯中，他还担任财务规划和分析经理。他的职业生涯始于通用电气航空航天部门的财务管理项目，后来担任财务分析和内部审计职位。他获得The Wharton School of Business，Pennsylvania大学的工商管理硕士学位，以及Bucknell大学的工商管理学士学位。
William J. Peters has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since August 2022, Amphastar Pharmaceuticals, Inc.'s Chief Financial Officer, Executive Vice President and Treasurer since May 2021 and was Amphastar Pharmaceuticals, Inc.'s Chief Financial Officer and Treasurer since April 2014, and as Amphastar Pharmaceuticals, Inc.'s President of International Medication Systems, Limited (a wholly owned subsidiary of Amphastar) since March 2016. Mr. Peters previously served as Chief Financial Officer of Hi Tech Pharmacal Co., Inc., or Hi Tech, from May 2004 to April 2014. From September 2003 to May 2004 he was Vice President of Corporate Development at Hi Tech. From 2001 to 2003 Mr. Peters was the Director, Financial Evaluations for the Medco Health Solution subsidiary of Merck & Co., Inc., or Merck & Co., and during his seven year career at Merck & Co., he also served in several positions of increasing responsibility. He began his career in General Electric's Financial Management Program, at its Aerospace division, where he later held positions in financial analysis and internal auditing. He earned an M.B.A. from The Wharton School of Business, of the University of Pennsylvania and a B.S. in Business Administration from Bucknell University.- William J. Peters，自2014年4月起担任首席财务官、高级副总裁兼财务主管，自2016年3月起担任International Medication Systems， LimitedAmphastar Pharmaceutical的子公司总裁。2013年8月至2014年4月，Peters先生担任high - tech pharmaceutical Co., Inc. （high - tech）的执行副总裁兼首席财务官；2004年5月至2013年8月，担任high - tech的副总裁兼首席财务官。从2003年9月到2004年5月，他担任high - tech公司的企业发展副总裁。从2001年到2003年，他担任Merck & Co., Inc.的Medco Health Solution子公司的财务评估总监；从1998年到2001年，担任Merck & Co.的企业财务分析和药物经济学经理。在Merck & Co的7年职业生涯中，他还担任财务规划和分析经理。他的职业生涯始于通用电气航空航天部门的财务管理项目，后来担任财务分析和内部审计职位。他获得The Wharton School of Business，Pennsylvania大学的工商管理硕士学位，以及Bucknell大学的工商管理学士学位。
- William J. Peters has served as a member of Amphastar Pharmaceuticals, Inc.'s Board of Directors since August 2022, Amphastar Pharmaceuticals, Inc.'s Chief Financial Officer, Executive Vice President and Treasurer since May 2021 and was Amphastar Pharmaceuticals, Inc.'s Chief Financial Officer and Treasurer since April 2014, and as Amphastar Pharmaceuticals, Inc.'s President of International Medication Systems, Limited (a wholly owned subsidiary of Amphastar) since March 2016. Mr. Peters previously served as Chief Financial Officer of Hi Tech Pharmacal Co., Inc., or Hi Tech, from May 2004 to April 2014. From September 2003 to May 2004 he was Vice President of Corporate Development at Hi Tech. From 2001 to 2003 Mr. Peters was the Director, Financial Evaluations for the Medco Health Solution subsidiary of Merck & Co., Inc., or Merck & Co., and during his seven year career at Merck & Co., he also served in several positions of increasing responsibility. He began his career in General Electric's Financial Management Program, at its Aerospace division, where he later held positions in financial analysis and internal auditing. He earned an M.B.A. from The Wharton School of Business, of the University of Pennsylvania and a B.S. in Business Administration from Bucknell University.